Today, Sandoz announced that the EMA has accepted its Marketing Authorization Application for its biosimlar to Amgen’s Neulasta, used to prevent infection in patients with compromised immune systems due to chemotherapy. Sandoz’s application is supported by three pivotal clinical trials.
Related Content
- Big Molecule WatchApril 18, 2024
Genentech and Dr. Reddy’s Settle BPCIA Rituximab Litigation
- Big Molecule WatchApril 17, 2024
MDL Panel Grants Transfer of Aflibercept BPCIA Case
- Big Molecule WatchApril 11, 2024
FDA Approves BMS and J&J CAR-T Cell Therapies for the Earlier Treatment of Multiple Myeloma
- Big Molecule WatchApril 9, 2024
FDA Approves New Indication for AstraZeneca and Daiichi Sankyo’s Cancer Drug ENHERTU
- Big Molecule WatchMarch 29, 2024
REGENXBIO and Sarepta Agree to Stay Litigation Pending Outcome of Sarepta’s IPR Petition
- Big Molecule WatchMarch 28, 2024
Fresenius Kabi and Formycon Reach Settlement Agreement for Ustekinumab Biosimilar Candidate in Europe and Canada
- Big Molecule WatchMarch 28, 2024
FDA Approves First Gene Therapy to Treat Children with Metachromatic Leukodystrophy
- Big Molecule WatchMarch 27, 2024
Biden Administration Proposes Biosimilar Substitution Without Interchangeability
- Awards and RankingsSeptember 25, 2023
Goodwin Named an LMG Life Sciences Life Cycle Firm for the Twelfth Consecutive Year
- Awards and RankingsOctober 4, 2022
LMG Recognizes Goodwin Lawyers and Practices for Excellence in Life Sciences
- Press ReleaseNovember 17, 2021
Goodwin Releases Update to its Comprehensive Guide to Biosimilars Litigation and Regulation in the U.S.
- Awards and RankingsOctober 26, 2021
Goodwin Named an LMG Life Sciences Life Cycle Firm for the Tenth Consecutive Year
- Press ReleaseJune 28, 2021
Goodwin Adds Life Sciences and Healthcare Litigation Partner William Jackson
- EventsDecember 5, 2020
China's Patent Linkage System: Can Strategies that Work in the U.S. System Be Applied to China?
- Awards and RankingsOctober 5, 2020
Goodwin Named An LMG Life Sciences Life Cycle Firm For The Ninth Consecutive Year
- Speaking EngagementsSeptember 23, 2020
ACI's 11th Summit on Biosimilars & Innovator Biologics